Oxylanthanum carbonate - Unicycive Therapeutics
Alternative Names: Lanthanum dioxycarbonate; OLC; RENALAN™; RenaZorb; RZB-014; SPI-014 - Assertio TherapeuticsLatest Information Update: 03 Jun 2024
At a glance
- Originator Altair Nanotechnologies
- Developer Assertio Therapeutics
- Class Hyperphosphataemia therapies; Lanthanoid series elements; Small molecules
- Mechanism of Action Phosphate binding modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Hyperphosphataemia
Most Recent Events
- 03 Jun 2024 Unicycive Therapeutics anticpates FDA approval in Hyperphosphatemia by the middle of 2025
- 03 Jun 2024 Unicycive Therapeutics plans to submit NDA to the US FDA for Hyperphosphatemia in the middle of 2024
- 31 May 2024 Unicycive Therapeutics has patent protection for oxylanthanum carbonate in US, Canada, Europe, Japan, China, Australia, and other countries